Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
11.43
+0.39 (3.53%)
At close: May 12, 2026, 4:00 PM EDT
11.43
0.00 (0.00%)
After-hours: May 12, 2026, 7:58 PM EDT
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
| Name | Position |
|---|---|
| Dr. Dominic Smethurst M.A., M.D. | Chief Medical Officer |
| Dr. Ian Hodgson B.Sc., Ph.D. | Chief Operating Officer |
| Dr. Yuval Cohen Ph.D. | CEO & Director |
| Mr. G. Scott Goeken J.D., M.S. | General Counsel & Corporate Secretary |
| Mr. Sean F. Moran CPA, M.B.A. | Chief Financial Officer |
| Ms. Christina Bertsch M.A. | Vice President of Human Resources |
| Date | Type | Document |
|---|---|---|
| 2026-04-16 | 8-K | crbp-20260415.htm |
| 2026-04-14 | 8-K | crbp-20260414.htm |
| 2026-04-07 | 8-K | crbp-20260401.htm |
| 2026-04-02 | DEF 14A | crbp-20260401.htm |
| 2026-03-11 | S-3 | crbp-20260311.htm |
| 2026-03-09 | 10-K | crbp-20251231.htm |
| 2026-02-25 | 8-K | crbp-20260225.htm |
| 2026-01-12 | 8-K | crbp-20260112.htm |
| 2025-12-18 | 8-K | crbp-20251212.htm |
| 2025-12-11 | 8-K | crbp-20251211.htm |